Plain-English translation of NCT06230822 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial tested , a treatment made from human stem cells, combined with standard lung disease medications in people with idiopathic pulmonary fibrosis (IPF)—a serious condition where lung tissue becomes scarred and stiff over time. Researchers gave participants three doses of the medication at different dose levels to see if it was safe and whether it could help slow or improve lung function. The trial followed a careful step-by-step approach, starting with the lowest dose and moving to higher doses only after confirming safety.
IPF is a serious disease that gradually worsens and has limited treatment options. This trial was designed to explore whether stem cell therapy could offer a new way to treat the condition and help people breathe better by reducing lung inflammation and scarring.
Participants received three intravenous injections of the medication on days 0, 3, and 6. Between injections and after the final dose, they underwent safety assessments including blood tests, heart monitoring, urine tests, physical exams, and lung function tests on day 3 and at other timepoints. A safety committee reviewed the results after each group of participants received their doses to decide whether it was safe to move forward with the next higher dose level.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
China